Format

Send to

Choose Destination
Nat Rev Drug Discov. 2008 Oct;7(10):827-40. doi: 10.1038/nrd2660.

The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Author information

1
GRB-804, Division of Cardiology, Massachusetts General Hospital, Boston, Massachussetts 02114, USA. rkakkar@partners.org

Abstract

For many years, the interleukin-1 receptor family member ST2 was an orphan receptor that was studied in the context of inflammatory and autoimmune disease. However, in 2005, a new cytokine--interleukin-33 (IL-33)--was identified as a functional ligand for ST2. IL-33/ST2 signalling is involved in T-cell mediated immune responses, but more recently, an unanticipated role in cardiovascular disease has been demonstrated. IL-33/ST2 not only represents a promising cardiovascular biomarker but also a novel mechanism of intramyocardial fibroblast-cardiomyocyte communication that may prove to be a therapeutic target for the prevention of heart failure.

PMID:
18827826
PMCID:
PMC4277436
DOI:
10.1038/nrd2660
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center